Dr. Mamounas on Adjuvant Endocrine Therapy for Breast Cancer
Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.
Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.
For years, many thought that 5 years of tamoxifen was the standard, states Mamounas. Studies had shown that additional therapy to around 10 years did not show any improvement.
However, with 15 years of follow-up, there has been a benefit in disease-free survival in patients receiving 10 years of tamoxifen, explains Mamounas.
